Zobrazeno 1 - 10
of 209
pro vyhledávání: '"L. Hovi"'
PP 7.8 – 00060 Slowing or Reversal of Decay of Intact Proviruses Over Two Decades of Suppressive ART
Autor:
J. Cyktor, R. Gandhi, R. Bosch, H. Mar, G. Laird, E. Halvas, L. Brandt, D. Mcmahon, J. Eron, J. Mellors, L. Hovind, S. Riddler, K. Ritter
Publikováno v:
Journal of Virus Eradication, Vol 8, Iss , Pp 100270- (2022)
Externí odkaz:
https://doaj.org/article/5cb5f236cd2a425ea8b9210fa180f7eb
Publikováno v:
Medical and pediatric oncology. 40(5)
Autor:
S L Hovi, Sirkka Lauri
Publikováno v:
European journal of cancer care. 8(4)
The purpose of this study was to examine hospitalised cancer patients' and nurses' assessment of patients' cancer pain and to compare them. The data were collected from 51 patient-nurse pairs in two hospitals from oncological and medical clinics. Eac
Publikováno v:
Acta paediatrica (Oslo, Norway : 1992). 87(2)
This study examined whether experience of cancer in childhood leaves a hypersensitivity to various somatic symptoms. Further, are self-reported somatic symptoms explained by medical late-effects or a worry of recurrence of the cancer?Of the total of
Autor:
M L, Hovi
Publikováno v:
The Veterinary record. 138(8)
Publikováno v:
Medical and pediatric oncology. 22(6)
The improved treatment of childhood leukemia is a major achievement. The late effects of the treatment need further investigation. Growth inhibition has been demonstrated in earlier studies. Growth and the timing of puberty were studied in 179 girls
Publikováno v:
Bone marrow transplantation. 8(5)
High-dose thiotepa was given as a single agent at a total dose of 1125 mg/m2 with autologous bone marrow rescue to nine patients with recurrent/refractory/poor risk pediatric malignancies (primitive neuroepithelial tumor (PNET), two; neuroblastoma, o
Publikováno v:
Bone marrow transplantation. 8
Autor:
S L, Hovi
Publikováno v:
Sairaanhoitaja (Helsinki, Finland : 1991). (7)
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the